Startups Elucidata and Auron Therapeutics signed a four-year deal to apply multi-omic data analytics for differentiation-based cancer therapies.
As Dana-Farber migrates its dozens of medical and radiation oncology protocols to the Philips platform, its focus is on digital pathology, genomics, and informatics.
The grant will support the consortium's ongoing efforts to clinically validate data analysis software for monitoring treatment responses to cancer vaccines.
The CATCH-KB database is a standardized variant repository meant to support new research into prevention of chemotherapy-induced cardiotoxicity.
Stand Up to Cancer is teaming with Microsoft and SITC to provide a new round of $11 million in grants to study cancer immunotherapies.
CEO Anders Rylander said the company will initially market its DiviTum assay for breast cancer cases, though it could be used to monitor cell proliferation in all cancer types.
The Belgian company recently received €3.6 million to develop the signature into a clinical test within the next three years.
The activity follows a recent financing round that has enabled OncoDNA to build out its sales team as it courts new clients.
The company is preparing a blood-based test for early-stage pancreatic cancer that it hopes to have on the market by 2019.
From targeted metagenomics on almost 300 soil samples, researchers saw evidence for microbiome gene clusters associated with natural product biosynthesis in NYC parks.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.